Geron Corp GERN

Alternate Symbol(s): GERNW

Healthcare Biotechnology

Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.

NDAQ:GERN - Post by User

Geron Corp

Bullboard Posts

Next >>

Post by AviseAnalyticson Jun 17, 2022 8:21am

213 Views

Post# 34763795

GERON CORPORATION: A LOT IS RIDING ON IMETELSTAT!

$GERN

Geron Corporation (NASDAQ: GERN) is a late-stage clinical biotechnology company developing a first-in-class telomerase inhibitor, imetelstat, intended to treat hematologic malignancies. A lot is riding on the topline results from the IMerge Phase 3 are expected to be announced in early January 2023.

We take a look at the Company in our article today!

Read on to know more:

https://www.aviseanalytics.com/geron-corporation-a-lot-is-riding-on-imetelstat/

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant